- van der Valk Fleur M., Bekkering Siroon, Kroon Jeffrey, Yeang Calvin, van den Bossche Jan, van Buul Jaap D., Ravandi Amir, Nederveen Aart J., Verberne Hein J., Scipione Corey, Nieuwdorp Max, Joosten Leo A. B., Netea Mihai G., Koschinsky Marlys L., Witztum Joseph L., Tsimikas Sotirios, Riksen Niels P., Stroes Erik S. G. Oxidized Phospholipids on Lipoprotein(a) Elicit Arterial Wall Inflammation and an Inflammatory Monocyte Response in Humans Circulation 2016;134 (8):611-624 [PubMed]
- Viney Nicholas J., van Capelleveen Julian C., Geary Richard S., Xia Shuting, Tami Joseph A., Yu Rosie Z., Marcovina Santica M., Hughes Steven G., Graham Mark J., Crooke Rosanne M., Crooke Stanley T., Witztum Joseph L., Stroes Erik S., Tsimikas Sotirios Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials Lancet 2016;388 (10057):2239-2253 [PubMed]
- Jakulj Lily, van Dijk Theo H., de Boer Jan Freark, Kootte Ruud S., Schonewille Marleen, Paalvast Yared, Boer Theo, Bloks Vincent W., Boverhof Renze, Nieuwdorp Max, Beuers Ulrich H. W., Stroes Erik S. G., Groen Albert K. Transintestinal Cholesterol Transport Is Active in Mice and Humans and Controls Ezetimibe-Induced Fecal Neutral Sterol Excretion Cell metabolism 2016;24 (6):783-794 [PubMed]
- Robinson Jennifer G., Farnier Michel, Krempf Michel, Bergeron Jean, Luc Gérald, Averna Maurizio, Stroes Erik S., Langslet Gisle, Raal Frederick J., El Shahawy Mahfouz, Koren Michael J., Lepor Norman E., Lorenzato Christelle, Pordy Robert, Chaudhari Umesh, Kastelein John J. P., Caccavo Alberto, Codutti Oscar, Gelersztein Elisabeth, Vico Marisa, Zaidman Cesar, Majul Claudio, Balthazar Yohan, Capiau Luc, Vrolix Mathias, Vermeersch Paul, Gotchev Dobromir, Todorov Georgi, Tumbev Haralin, Tzekova Maria, Gronkova Naydenka, Dimov Bojidar, Nikolaeva Antonoaneta, Devedzhiev Tsvetan, Mincheva Valentina, D'Ignazio Giuseppe, Dzongowski Peter, Elliott Thomas, Hart Randy, Hoag Gordon, Martinho Valdemar, O'Mahony Michael, Tellier Guy, Pandey Shekhar, Heaton Kenneth, Constance Christian, Phaneuf Denis-Carl, Shu Daniel, Narvaez Nancy Cardenas, Cañon Claudia Olivares Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events New England journal of medicine 2015;372 (16):1489-1499 [PubMed]
- Duivenvoorden Raphaël, Tang Jun, Cormode David P., Mieszawska Aneta J., Izquierdo-Garcia David, Ozcan Canturk, Otten Maarten J., Zaidi Neeha, Lobatto Mark E., van Rijs Sarian M., Priem Bram, Kuan Emma L., Martel Catherine, Hewing Bernd, Sager Hendrik, Nahrendorf Matthias, Randolph Gwendalyn J., Stroes Erik S. G., Fuster Valentin, Fisher Edward A., Fayad Zahi A., Mulder Willem J. M. A statin-loaded reconstituted high-density lipoprotein nanoparticle inhibits atherosclerotic plaque inflammation Nature communications 2014;5:3065 [PubMed]
Prof. MD PhD E.S.G. Stroes (Novel anti-atherogenic strategies targeting the vessel wall)
During the past decade the applicant has focused at the pathophysiology of atherogenesis, focusing at the role of the vessel wall as a potential new therapeutic target. In the quest to optimize therapeutic options for patients at increased cardiovascular diseases, several lines of research are being pursued:
Imaging: Early treatment of atherosclerotic disease requires careful phenotyping of patients and early detection of atherosclerotic disease. In collaboration with Nederveen (Dept radiology), the applicant has focused at 3T-magnetic resonance of predominantly the carotid artery as a surrogate marker for atherogenesis/cardiovascular disease.
In collaboration with Dr Hein Verberne (Nuclear medicine, AMC) the applicant has also focused at the vessel wall inflammation. Using translational protocols, the impact of inflammation throughout the course of atherogenesis is evaluated, using multi-modality imaging as well as innovative anti-inflammatory compounds.
Precision medicine: In collaboration with Prof Groen and Nieuwdorp, and dr Levin, deep-machine learning strategies are designed, aiming to unravel circulating plasma markers predicting presence/absence of atherosclerotic disease. This research is part of a ERA-CVD program, collaborating with Koenig (Munchen, Germany) and Catapano (Milano, Italy)
Residual risk: LDL lowering reduces CV risk by 30%, most likely limited by the fact that statins stabilize the disease without the potential to induce reversibility of the lesions. Novel exciting lipid particles are currently being addressed, which contribute to the residual risk following optimal LDLc lowering regimens. These comprise remnant cholesterol and Lp(a). Defining pro-atherogenic pathways and novel modalities to antagonize this effect complements the quest for novel anti-atherogenic compounds.
Faculty
Prof. MD PhD G.K. Hovingh
MEng PhD A.J. Nederveen
Prof. MD PhD M. Nieuwdorp
Postdocs
PhD M. Bahjat
PhD J. Kroon
Prof. MD PhD M. Nieuwdorp (Gutmicrobiota as novel diagnostic and therapeutic targets in cardiometabolism)
- AMC
- Amgen BV
- Athera Biotechnologies AB
- Daiichi/NIET GEBRUIKEN IS OUD ADRES!!
- IQVIA RDS Switzerland Sarl
- Inserm - DR Paris 7
- Nederlandse Hartstichting
- Portola Pharmaceuticals Inc.
- Regeneron Pharmaceuticals, Inc.
- Resverlogix Corp.
- Stichting AMC Foundation (Vrijgesteld)
- Synageva BioPharma Corp.
- UBC Late Stage (UK) Limited
- UMC Utrecht
- Vascular Research Network BV
- ZonMw (Vrijgesteld)